Ursodeoxycholic acid treatment of idiopathic thrombocytopenic purpura with liver dysfunction.
Ursodeoxycholic acid (UDCA) is known to reduce immunoglobulin from B cells and cytokine production from T cells. We found that UDCA increased the platelet count in two idiopathic thrombocytopenic purpura (ITP) patients who have liver dysfunction. UDCA was tolerated and did not cause diarrhea in the amounts used. Further investigation is needed to evaluate the effectiveness of UDCA in ITP patients.
Koike
Michiaki
M
Department of Internal Medicine, Juntendo University Izu-Nagaoka Hospital, Shizuoka, Japan. yu-koike@lily.ocn.ne.jp
Sekigawa
Iwao
I
Ogawa
Kaol
K
Iida
Noboru
N
Oshimi
Kazuo
K
D000328:Adult; D005234:Fatty Liver / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008107:Liver Diseases / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000150:complications / Q000188:drug therapy*; D014580:Ursodeoxycholic Acid / Q000494:pharmacology / Q000627:therapeutic use*
D014580:Ursodeoxycholic Acid